» Articles » PMID: 38389147

Pharmacologic Therapeutics in Sarcopenia with Chronic Kidney Disease

Overview
Specialty Nephrology
Date 2024 Feb 23
PMID 38389147
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammation, metabolic acidosis, renin-angiotensin system activation, insulin resistance, and impaired perfusion to skeletal muscles, among others, are possible causes of uremic sarcopenia. These conditions induce the activation of the nuclear factor-kappa B and mitogen-activated protein kinase pathways, adenosine triphosphate ubiquitin-proteasome system, and reactive oxygen species system, resulting in protein catabolism. Strategies for the prevention and treatment of sarcopenia in chronic kidney disease (CKD) are aerobic and resistance exercises along with nutritional interventions. Anabolic hormones have shown beneficial effects. Megestrol acetate increased weight, protein catabolic rate, and albumin concentration, and it increased intracellular water component and muscle mass. Vitamin D supplementation showed improvement in physical function, muscle strength, and muscle mass. Correction of metabolic acidosis showed an increase in protein intake, serum albumin levels, body weight, and mid-arm circumference. The kidney- gut-muscle axis indicates that dysbiosis and changes in gut-derived uremic toxins and short-chain fatty acids affect muscle mass, composition, strength, and functional capacity. Biotic supplements, AST-120 administration, hemodiafiltration, and preservation of residual renal function are alleged to reduce uremic toxins, including indoxyl sulfate (IS) and p-cresyl sulfate (PCS). Synbiotics reversed the microbiota change in CKD patients and decreased uremic toxins. AST-120 administration changed the overall gut microbiota composition in CKD. AST-120 prevented IS and PCS tissue accumulation, ameliorated muscle atrophy, improved exercise capacity and mitochondrial biogenesis, restored epithelial tight junction proteins, and reduced plasma endotoxin levels and markers of oxidative stress and inflammation. In a human study, the addition of AST-120 to standard treatment had modest beneficial effects on gait speed change and quality of life.

Citing Articles

Sarcopenia in Chronic Kidney Disease: A Narrative Review from Pathophysiology to Therapeutic Approaches.

Tsai C, Wang P, Hsiung T, Fan Y, Wu J, Kan W Biomedicines. 2025; 13(2).

PMID: 40002765 PMC: 11852367. DOI: 10.3390/biomedicines13020352.


Associations of MRI-derived kidney volume, kidney function, body composition and physical performance in ≈38 000 UK Biobank participants: a population-based observational study.

Cho J, Koh J, Kim S, Lee S, Kim Y, Cho S Clin Kidney J. 2024; 17(4):sfae068.

PMID: 38660121 PMC: 11040514. DOI: 10.1093/ckj/sfae068.

References
1.
Cruz-Jentoft A, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T . Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2018; 48(1):16-31. PMC: 6322506. DOI: 10.1093/ageing/afy169. View

2.
Kikuchi M, Ueno M, Itoh Y, Suda W, Hattori M . Uremic Toxin-Producing Gut Microbiota in Rats with Chronic Kidney Disease. Nephron. 2016; 135(1):51-60. DOI: 10.1159/000450619. View

3.
Isoyama N, Qureshi A, Avesani C, Lindholm B, Barany P, Heimburger O . Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. Clin J Am Soc Nephrol. 2014; 9(10):1720-8. PMC: 4186520. DOI: 10.2215/CJN.10261013. View

4.
Enoki Y, Watanabe H, Arake R, Sugimoto R, Imafuku T, Tominaga Y . Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1. Sci Rep. 2016; 6:32084. PMC: 4994088. DOI: 10.1038/srep32084. View

5.
Niwa T, Yazawa T, Maeda K, Ise M, Sugano M, Kodama T . [Effect of oral sorbent, AST-120, on serum concentration of indoxyl sulfate in uremic rats]. Nihon Jinzo Gakkai Shi. 1990; 32(6):695-701. View